Please ensure Javascript is enabled for purposes of website accessibility

Why Vir Biotechnology Stock Skyrocketed Today

By Joe Tenebruso - Updated Jan 26, 2021 at 5:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The immunology specialist is seeking a cure for hepatitis B.

What happened 

Shares of Vir Biotechnology (VIR -4.06%) soared 74% on Tuesday after the immunology company released promising results from an early-stage study of its experimental antibody treatment for the hepatitis B virus (HBV). 

So what

Preliminary data from Vir Biotechnology's phase 1 trial of its subcutaneously administered monoclonal antibody, VIR-3434, showed a marked reduction in HBV surface antigen levels in patients with chronic HBV infection.

A person is pointing to an upwardly sloping line.

Vir Biotechnology's stock surged on Tuesday. Image source: Getty Images.

Better still, Vir Biotechnology engineered VIR-3434 to include a vaccinal mutation that could potentially allow it to function as a T cell vaccine against HBV.

"The need for a functional cure for the nearly 300 million people living with chronic HBV is paramount," Dr. Kosh Agarwal, the lead study investigator, said in a press release. "Lowering HBsAg [the HBV virus surface antigen] may help unlock a patient's immune system, allowing it to provide the immune control necessary to achieve a functional cure."

Now what

In addition to its HBV treatment, Vir Biotechnology also designed its experimental COVID-19 antibody therapy, VIR-7832, to include the XX2 vaccinal mutation technology, to which it has exclusive rights. The company plans to begin a phase 1b/2a trial of VIR-7832 in the coming weeks.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
VIR
$24.84 (-4.06%) $-1.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.